23 Nov
2021

Novo Nordisk’s $3.3 billion Dicerna purchase shows booming RNA IP market

The multi-billion-dollar acquisition of RNAi rights holder Dicerna shows that mRNA innovations are not the only RNA-related assets in hot demand.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth